Understanding How Coronavirus Disguises Itself to Hide Inside Host Cells and Replicate May Help Develop COVID-19 Treatment
|
By HospiMedica International staff writers Posted on 28 Jul 2020 |

Illustration
Researchers have discovered that the SARS-CoV-2 virus molecules make themselves unrecognizable to host cells by tricking the immune system with camouflage, thus paving the way for drug development for the treatment of COVID-19.
Researchers at The University of Texas Health Science Center (San Antonio, TX, USA) resolved the structure of an enzyme called nsp16, which the coronavirus produces and then uses to modify its messenger RNA cap. These modifications fool the cell, as a result of which the viral messenger RNA becomes considered as part of the cell’s own code and not foreign. Deciphering the 3D structure of nsp16 paves the way for rational design of antiviral drugs for COVID-19 and other emerging coronavirus infections, according to Dr. Yogesh Gupta, PhD, the study lead author from the Joe R. and Teresa Lozano Long School of Medicine at UT Health San Antonio. The drugs, new small molecules, would inhibit nsp16 from making the modifications. The immune system would then pounce on the invading virus, recognizing it as foreign.
“Yogesh’s work discovered the 3D structure of a key enzyme of the COVID-19 virus required for its replication and found a pocket in it that can be targeted to inhibit that enzyme. This is a fundamental advance in our understanding of the virus,” said study coauthor Robert Hromas, MD, professor and dean of the Long School of Medicine.
Related Links:
The University of Texas Health Science Center
Researchers at The University of Texas Health Science Center (San Antonio, TX, USA) resolved the structure of an enzyme called nsp16, which the coronavirus produces and then uses to modify its messenger RNA cap. These modifications fool the cell, as a result of which the viral messenger RNA becomes considered as part of the cell’s own code and not foreign. Deciphering the 3D structure of nsp16 paves the way for rational design of antiviral drugs for COVID-19 and other emerging coronavirus infections, according to Dr. Yogesh Gupta, PhD, the study lead author from the Joe R. and Teresa Lozano Long School of Medicine at UT Health San Antonio. The drugs, new small molecules, would inhibit nsp16 from making the modifications. The immune system would then pounce on the invading virus, recognizing it as foreign.
“Yogesh’s work discovered the 3D structure of a key enzyme of the COVID-19 virus required for its replication and found a pocket in it that can be targeted to inhibit that enzyme. This is a fundamental advance in our understanding of the virus,” said study coauthor Robert Hromas, MD, professor and dean of the Long School of Medicine.
Related Links:
The University of Texas Health Science Center
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Artificial Intelligence
view channel
Automated Phone Speech Test Identifies Alzheimer’s Pathology for Prescreening
Alzheimer’s disease assessment and trial recruitment often rely on costly, invasive biomarker testing and clinic-based cognitive evaluations, limiting scalability as populations age. Providers and trial... Read more
FDA-Cleared AI System Detects Sepsis Earlier and Reduces Mortality
Sepsis remains one of the deadliest complications for hospitalized patients, in part because its early signs overlap with other conditions. Each hour of delayed recognition measurably decreases survival,... Read moreCritical Care
view channel
Implantable Wireless Light Device Advance Bladder Cancer Treatment
Bladder cancer, a malignancy of the urinary bladder, often requires local therapies that spare surrounding tissue. Photodynamic therapy uses light-activated drugs but is limited by poor light penetration... Read more
AI-Enabled Wearable Patches Reveal Undetected Hormone Disruption in Infertility
Unexplained infertility, diagnosed when routine evaluations identify no clear cause, affects 15–30% of couples and often leaves patients with limited options. Standard testing typically captures hormone... Read moreSurgical Techniques
view channel
BD Launches Elyra Laser Platform for Kidney Stone and Soft Tissue Procedures
BD (Becton, Dickinson and Company) has introduced the Elyra Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete its kidney stone care portfolio for urology teams.... Read more
Stretchable Bioelectronic Implant Lowers Blood Pressure in Preclinical Study
Hypertension, or high blood pressure, drives major cardiovascular morbidity and affects nearly half of adults in the United States. About one in ten patients develop drug‑resistant hypertension that persists... Read more
FDA-Cleared Nerve Stimulator Advances Intraoperative Peripheral Nerve Assessment
The Evala Nerve Stimulator from Epineuron (Mississauga, ON, Canada) is a handheld, intraoperative electrical stimulation system designed to provide surgeons with a rapid and accurate method for nerve identification... Read morePatient Care
view channel
AI Avatar Doctor Improves Patient Understanding Before Radiotherapy
Radiation oncology consultations require patients to grasp complex concepts quickly, yet anxiety and information overload often undermine understanding and informed consent. Poor comprehension can also... Read more
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read moreHealth IT
view channel
EHR-Integrated Screening Workflow Detects Cognitive Impairment at Admission
Cognitive impairment involves difficulties with thinking, learning, memory, and decision-making, and is more common in older adults. In U.S. hospitals, more than 40% of admitted older adults have dementia,... Read more
AI System Detects and Quantifies Chronic Subdural Hematoma
Viz.ai (San Francisco, CA, USA) announced a strategic commercialization collaboration with Johnson & Johnson (New Brunswick, NJ, USA) to expand access in the United States to the Viz Subdural solution... Read more
Continuous Monitoring Platform Detects Infection Risk Across Care Transitions
Patients leaving skilled nursing facilities often lose continuous physiologic monitoring, increasing the risk of undetected infection and delayed intervention. Nursing home residents are seven times more... Read more
Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings
Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read morePoint of Care
view channel
Point-of-Care Viscoelastic Testing System Supports Obstetric Bleeding Management
HemoSonics (Durham, NC, USA) announced on May 5, 2026 that the company's Quantra Hemostasis System for Obstetric Procedures won Silver in the 2026 Edison Awards in the Women’s Health and Reproductive Innovations... Read moreBusiness
view channel
Olympus Partnership Aims to Expand Access to Robot-Assisted Endoscopic Therapy
Olympus has signed an exclusive global distribution agreement with EndoRobotics Co., Ltd., under which robot-assisted technologies developed by EndoRobotics will be distributed worldwide as part of the... Read more








